SCHEMBL20098037

SCHEMBL20098037

CC1(Nc2nc3ccccc3o2)N=C(c2ccccc2)c2ccccc2NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
TDP1 Q9NUW8 3/20 0.40
GAA P10253 3/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HIF1A Q16665 1/20 0.40
GALK1 P51570 5/20 0.38
MAPT P10636 3/20 0.38
USP2 O75604 1/20 0.38
RAB9A P51151 5/20 0.38
ALDH1A1 P00352 2/20 0.38
PKM P14618 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20098036 0.78 ALDH1A1 (0.41) NPC1SMN1; SMN2KDM4ELMNARAB9A
SCHEMBL20098666 0.78 GABRA1 (0.39) GAALMNAMAPTALDH1A1GABRA1
SCHEMBL21117035 0.77 CCKAR (0.38) GAALMNAMAPTALDH1A1GABRA1
SCHEMBL20098035 0.77 STK10 (0.39) NPC1SMN1; SMN2TDP1GAAMAPT
SCHEMBL20098184 0.76 ADCY1 (0.43) SMN1; SMN2TDP1KDM4ELMNAUSP2
SCHEMBL21755197 0.76 ADCY1 (0.43) SMN1; SMN2TDP1KDM4ELMNAUSP2
SCHEMBL20098024 0.73 CCKBR (0.52)
SCHEMBL5803308 0.71 GABRA1 (0.53) GAAKDM4ELMNAMAPTALDH1A1
SCHEMBL21755152 0.69 GABRA1 (0.50) GAAKDM4ELMNAMAPTALDH1A1
SCHEMBL22022340 0.69 GABRA1 (0.50) GAAKDM4ELMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-01-05 US disclosed
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-15 US disclosed
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2020-07-16 US disclosed
US-10570153-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-02-25 US disclosed
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-06-27 US disclosed
US-9957281-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2018-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 NPC1 224/4885SMN1; SMN2 627/4885TDP1 3446/4885
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors SERPINB1, FURIN, HIF1AN NPC1 480/4885SMN1; SMN2 709/4885TDP1 4500/4885
US-10570153-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 NPC1 224/4885SMN1; SMN2 627/4885TDP1 3446/4885
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 NPC1 224/4885SMN1; SMN2 627/4885TDP1 3446/4885
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS SERPINB1, FURIN, HIF1AN NPC1 480/4885SMN1; SMN2 709/4885TDP1 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.